<DOC>
	<DOCNO>NCT01995578</DOCNO>
	<brief_summary>The purpose study learn 5'-Azacitidine help low risk disease come back stem cell transplant patient MDS AML . This study also look side effect medicine . 5'-Azacitidine FDA approve drug treatment MDS AML , well patient whose disease come back transplant , help go remission . It unclear 5'-Azacitidine prevent disease come back transplant . This study help show get 5'-Azacitidine soon transplant low risk disease come back .</brief_summary>
	<brief_title>Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation Patients With Myelodysplastic Syndrome Acute Myelogenous Leukemia With High Risk Post-Transplant Relapse</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Patients undergone T cell deplete allogeneic hematopoietic stem cell transplantation MSKCC : De novo myelodysplastic syndrome ( MDS ) : IPSS1 poor risk cytogenetics higher IPSS . Acute myelogenous leukemia ( AML ) first remission require 1 cycle treatment achieve remission follow cytogenetic abnormality : FLT3 mutation , deletion/monosomy chromosome 5 7 , MLL gene rearrangement , equal 3 cytogenetics abnormality . Also patient second great remission . Patients Secondary MDS/AML . Patients consider eligible study transplant achieve hematologic ( &lt; 5 % blast ) cytogenetic remission . Patients eligible enter study 60120 day post transplant . Age : pediatrics adults patient 1 year old75 year old . Karnofsky performance status &gt; =60 % patient &gt; 16yo Lansky performance status &gt; =60 % patient â‰¤16yo Stable blood count ( ANC &gt; 1000/uL , Hb &gt; 8gr/dL , Plt &gt; 50,000/ uL ) support transfusion . Renal : Serum creatinine &lt; 1.5 ULN Hepatic : &lt; 3xULN ALT &lt; 1.5 total serum bilirubin , unless congenital benign hyperbilirubinemia . Cardiac : Adequate cardiac function measure LVEF &gt; 50 % . If asymptomatic , pretransplant echocardiogram adequate . If symptomatic , echocardiogram need repeat . Each patient must willing participate research subject must sign informed consent form . Patients exclude trial time enrollment : Active uncontrolled bacterial , fungal viral infection . Evidence uncontrolled graftversushost disease . Pulmonary : new onset hypoxia Known suspect hypersensitivity 5'azacitadine mannitol . Evidence residual disease either increase blast count ( &gt; 5 % ) persistence previous know cytogenetics abnormality . Peripheral blood neutrophil chimerism : le 95 % donor .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>5'-Azacitidine</keyword>
	<keyword>Stem cell transplant</keyword>
	<keyword>13-192</keyword>
</DOC>